Background. Faecal calprotectin is considered to be a valid test for ruling out inflammatory bowel disease (IBD) in children with chronic gastrointestinal symptoms in specialist care. In contrast, faecal lactoferrin has higher specificity. The recent availability of both as point-of-care tests (POCTs) makes them attractive for use in primary care. Objective. To evaluate the test characteristics of calprotectin and lactoferrin POCTs for diagnosing IBD in symptomatic children. Methods. We defined two prospective cohorts of children with chronic gastrointestinal symptoms: (i) children presenting to primary care (primary care cohort); (ii) children referred for specialist care (referred cohort). Baseline POCT results were compared with the outcome of either endoscopic assessment or 12 months follow-up. Clinicians were blinded to the POCT results. Results. In the primary care cohort, none of the 114 children had IBD, and the calprotectin and lactoferrin POCTs had specificities of 0.95 (0.89-0.98) and 0.98 (0.93-0.99), respectively. In the referred cohort, 17 of the 90 children had IBD: the sensitivity of POCT calprotectin and POCT lactoferrin were both 0.94 (0.72-0.99); and the specificity was 0.93 (0.84-0.97) and 0.99 (0.92-1.00), respectively. The POCT calprotectin could reduce the referral rate by 76% and POCT lactoferrin by 81%, while missing one child with IBD (6%). Conclusion. A diagnostic test strategy in primary care using a simple POCT calprotectin or lactoferrin has the potential to reduce the need for referral for further diagnostic work-up in specialist care, with a low risk of missing a child with IBD.
Introduction
In primary care, it can be difficult to differentiate between functional gastrointestinal disorders and organic disease, such as inflammatory bowel disease (IBD). Indeed, specialist care referral can ensure early diagnosis and treatment of children with IBD, and thereby reduce complications (1) . Typically, referral is recommended for children with high-risk features, such as rectal bleeding, weight loss, or a family history of IBD (2) . These high-risk features, however, are common and have little discriminative power (3, 4) . Therefore, simple, accurate tests are needed that can differentiate between functional and organic disorders in children with chronic gastrointestinal symptoms.
Faecal calprotectin, a non-invasive test for intestinal inflammation, has a high rule-out value among symptomatic children in specialist care (high sensitivity, reduced post-test probability of a normal test result) (5) (6) (7) . We have also shown a high rule-out value in children presenting in primary care (8) . In both settings, faecal calprotectin was measured by enzyme-linked immunosorbent assays (ELISA); however, point-of-care tests (POCT) have been developed with comparable accuracy to the ELISA (9) . The concentration of calprotectin is stable at room temperature for 7 days, and only a few grams of stool are required. This enables the patient to deliver a stool sample at the general practice and receive a test result within 15 minutes. Whereas faecal calprotectin, with its high sensitivity, is the most used faecal diagnostic test in children suspected for IBD, faecal lactoferrin has been shown to have a high specificity for IBD (10, 11) . Thus, lactoferrin might be of additional diagnostic value when used in combination with faecal calprotectin in point-of-care testing.
To date, the diagnostic accuracy of the calprotectin POCT, lactoferrin POCT and the combination of both, has not been examined for IBD among children with chronic gastrointestinal symptoms in primary care. Therefore, we studied the test characteristics in children presenting in primary care and children referred to specialist care.
Methods

Design and patients
This was a prospective cohort study with a delayed-type cross-sectional design (12) . Children were included in the Netherlands from July 2011 to July 2013 and were followed for 12 months. Parents of all children, and children aged ≥12 years, provided written informed consent, as appropriate. The study protocol was approved by the medical ethics committee of the University Medical Centre Groningen.
We included two cohorts of children with chronic gastrointestinal symptoms. The primary care cohort included consecutive children recruited by 64 participating general practitioners (GPs) from 38 practices. The referred cohort included children selected from the primary care cohort who were referred for specialist care based on the presence of ≥1 high-risk features, and consecutive children referred by GPs and paediatricians who were included at one of four general hospitals and three academic centres.
The inclusion criteria were age 4-18 years, chronic diarrhoea (score 5, 6 or 7 on the Bristol Stool Form Scale (13) for ≥2 weeks or ≥2 episodes in the past 6 months) and/or recurrent abdominal pain (≥2 episodes of abdominal pain or discomfort in the past 6 months). Exclusion criteria were known chronic organic gastrointestinal disease; endoscopic evaluation or faecal calprotectin testing in the preceding 6 months; chronic use of antibiotics, non-steroid antiinflammatory drugs or oral corticosteroids in the previous 6 months; or difficulties in understanding questionnaires.
Patient flow
At baseline, the study GP or paediatrician assessed the presence of involuntary weight loss, rectal bleeding, family history of IBD, growth failure, extra-intestinal symptoms and peri-anal lesions, based on a structured history and physical exam. In addition, a blood sample (for assessment of haemoglobin, C-reactive protein, erythrocyte sedimentation rate and platelet count) was taken (see high-risk features, Table 1 ). All children were clinically followed for 12 months. Children with ≥1 high-risk feature (Table 1) at baseline or after 12 months' follow-up were referred to a paediatric gastroenterologist who decided whether the child required endoscopic evaluation based on global assessment, physical examination and blood test results. Children who did not had an indication for endoscopy received the reference standard of a clinical 12 months follow-up, because it was thought to be unethical to perform an invasive procedure under full anaesthesia in children with a low likelihood of IBD. The GPs or paediatricians of children lost to follow-up were contacted after 12 months in order to receive the most recent information required for making the final diagnosis.
Point-of-care testing
A stool sample tube, together with information on how to collect a stool sample, was provided at baseline. Stool was collected at home, shortly after inclusion and sent to a laboratory for storage at −80°C until data collection was complete (September 2014). We The stick of the stool collection tube was dipped into different parts of the stool sample and added to the extraction buffer in the stool collection tube; or, for liquid samples, 15 μl was pipetted into the stool collection tube. The tube was shaken to ensure good sample distribution. Four drops from the sample in the stool collection tube were added to both windows of the POCT device (Window A for calprotectin and Window B for lactoferrin) and the results were read after 10 minutes. If a red-coloured line appeared in either window, the respective test was positive. The thresholds for positivity were >50 μg/g faeces and >10 μg/g faeces for the calprotectin and lactoferrin tests, respectively. The results were invalid when the green control line was absent. The testers were blinded to the clinical characteristics and diagnosis, and all clinicians and researchers were blinded to the outcomes of both POCTs.
Diagnosis
IBD was diagnosed by oesophagogastroduodenoscopy and ileocolonoscopy with histopathology of multiple biopsies, according to the revised Porto Criteria (16) . Absence of IBD was defined as no endoscopic and histopathological evidence of IBD and/or no indication for endoscopy within or at 12 months' follow-up.
Statistical analysis
A simple and non-invasive POCT might convince the GP to use this test in children with a low likelihood of IBD. In this population, false-positive results should be minimized to avoid unnecessary referrals for endoscopy. Therefore, we were mostly interested in a precise estimate of the specificity of both POCT results in the primary care cohort. A sample size calculation, which was based on a IBD prevalence rate of 5%, loss to follow-up of 10% and specificity of 93%, generated a total of 118 children to determine the specificity with 95% confidence intervals (CIs) and adequate precision (i.e. 5%) (12) . In children in whom the GP considers a referral the likelihood of IBD increases. In this population, low false-negative rates are important to prevent delay in the diagnoses of children with IBD. Therefore, we were mostly interested in a precise estimate of sensitivity of both POCTs in the referred cohort. Based on a IBD prevalence rate of 20%, loss to follow-up of 10% and sensitivity of 95%, we calculated a sample size of 100 children to determine sensitivity with 95% CIs and adequate precision (i.e. 10%) (12) . Moreover, we calculated specificity, positive predictive value (PPV), negative predictive value (NPV) with 95% CIs separately for each POCT in the referred cohort. In order to evaluate spectrum bias, subgroup analyses in children who were referred (1) by GP and (2) by general paediatrician were performed. To evaluate the accuracy of the structured clinical assessment in this study, we compared the proportion of children with high-risk features and the proportion of children with IBD in children with and without an endoscopy at baseline. Moreover, we evaluated the potential clinical impact of the different test results on referral rate or missed IBD diagnosis of the dual calprotectin-lactoferrin POCT with scenario analysis in the primary care cohort and referred cohort. We performed complete case analyses, because the number of missing values were neglectable. Statistical analyses were performed with IBM SPSS for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA).
Results
Descriptive characteristics
The participant flow and baseline characteristics are summarized in Figure 1 and Table 2 . We included 114 and 90 children in the primary care cohort and referred cohort, respectively. None of the primary care cohort and 17 (19%) of the referred cohort were diagnosed with IBD (Supplementary Table S1 ). In the referred cohort, children referred by a general paediatrician more frequently had involuntary weight loss, rectal bleeding and extra-intestinal symptoms, and were more likely to be diagnosed with IBD, when Figure 1 . Patient flow in the study. We included 114 children in the primary care cohort, of whom 24 were referred to specialist care based on ≥1 high-risk features, 2 underwent endoscopy at baseline and 112 were followed for 12 months. We included 90 children in the referred cohort, of whom 65 (72%) were referred by a GP and 25 (28%) were referred by a general paediatrician. At baseline, 25 children underwent endoscopic and histopathological evaluation, and during follow-up, 4 children underwent endoscopy. The remaining 61 children had no indication for endoscopy during the 12 months' follow-up. Children who were primarily seen in primary care, but who were referred to specialist care, were evaluated in both analyses. Point-of-care testing was not performed in 12 children because faecal samples were not collected (n = 9), were not stored at the laboratory (n = 2) or were insufficient for analysis (n = 1). 5 (8) 1 (17) 1.000
Extra-intestinal symptoms 0 (0)
13 (14) 4 (6) 9 (36) 0.001
6 (9) 7 (28) 0.041
Peri-anal lesions 7 (6) 13 (14) 9 (14) 4/24 (17) 1.000 4/61 (7) 3 (12) 0.668 4/61 (7) 3 (12) 0.409
High-risk features (n (%))
29 (25) 68 (76) 43 (66) 25 (100) 0.001
43 (66) 25 (100) 0.000
29 (32) 9 (14) 20 (80) 0.000
4 (6) 25 (100) 0.000
5/64 (8) 12 (48) 0.000
2 (3) 15 (60) 0.000
Crohn's disease Children were also referred by GPs who did not participate in this study.
The P values should be interpreted with caution, because there is a risk of type 1 error due to a low power.
compared with the children referred by a GP. Children who were subjected to an endoscopy at baseline had more frequently highrisk features (100%) and high risk for IBD (60%) than children who underwent no endoscopy at baseline (66% and 3%, respectively) ( Table 2 ). The median intervals between faecal sampling and endoscopy were 4 and 8 days for children with and without IBD, respectively; however, 11 of the 27 children (2 missing samples) who underwent endoscopy had a delay >1 month. POCTs were not performed in 12 children, and 9 test results (7.9%) were missing in the primary care cohort and 5 (5.6%) in the referred cohort.
The POCT characteristics
The characteristics of the calprotectin and lactoferrin POCTs for IBD, in children in primary care cohort and referred cohort are detailed in Table 3 . In the primary care cohort, specificity of POCT calprotectin and POCT lactoferrin were 0.95 (0.89-0.98) and 0.98 (0.93-0.99), respectively. In the referred cohort, sensitivity of POCT calprotectin and POCT lactoferrin were both 0.94 (0.72-0.99); and the specificity was 0.93 (0.84-0.97) and 0.99 (0.92-1.00), respectively. In a subgroup analysis, the sensitivity of both POCTs in children referred to specialist care by their GP was 1.00 (0.57-1.00), the specificity for POCT calprotectin was 0.93 (0.84-0.97) and for POCT lactoferrin 1.00 (0.94-1.00). The sensitivity and specificity of both POCTs in children referred to specialist care by their general paediatrician were 0.91 (0.62-0.93). Table 4 shows that in primary care cohort 97% of the children had the same outcome for both POCTs and in referred cohort 95%. In the primary care cohort, a normal POCT calprotectin and lactoferrin could hypothetically reduce 95% of referrals of children with high-risk features compared to referral of all children with high-risk features without missing a child with IBD. In the referred cohort, a normal POCT calprotectin and lactoferrin could hypothetically reduce referrals by 76%, compared to referral of all children considered for referral, but with the risk that 1 child (6%) with IBD would be missed (Table 4) .
Scenario analysis
Discussion
Summary
The POCTs showed high specificities in children presenting with chronic gastrointestinal symptoms in primary care, none of which were diagnosed with IBD. In children referred for further diagnostic work-up, both POCTs showed high sensitivities and negative predictive values. In both cohorts 95% or more of the children had the same outcome for both POCTs, which indicates that the tests provided little additional value to one another. FCal, faecal calprotectin; FLacto, faecal lactoferrin; NPV, negative predictive value; POCT, point-of-care test; PPV, positive predictive value sens, sensitivity; spec, specificity. None of the children in primary care cohort were diagnosed with IBD. The test strategies are based on the assumption that children with both normal POCTs results should not be referred and both positive POCTs results should be referred. We showed both the impact on referrals and reduction of referrals for a combination of positive and normal result. Missing POCT: two children with high-risk features in primary care cohort; seven children without high-risk features in primary care cohort; five children in referred cohort; one child with IBD.
FCal, faecal calprotectin; FLacto, faecal lactoferrin; +, positive POCT; −, normal POCT; POCT, point-of-care test.
Strengths and limitations
Evaluating test characteristics is a challenge when the prevalence of a disease is very low: a case-control design would overestimate test characteristics, while the preferred method of including consecutive at-risk children would be extremely time consuming and costly. In addition, using an invasive reference standard, risks exposing healthy children unnecessarily and would be ethically intolerable. Nevertheless, test characteristics urgently need to be evaluated in primary care (17) . Based on this need, we used a pragmatic design that included consecutive children presenting with chronic gastrointestinal symptoms in primary care and selected high-risk children who were referred for specialist care (12) . As expected, the prevalence and severity of IBD differed between these groups. In the referred cohort, children referred by a general paediatrician were more severely ill than children referred by their GP. This finding might reflect that, in the Netherlands, a paediatric gastroenterologist can see children if they are directly referred by a GP or indirectly referred by a paediatrician. Comparable healthcare systems exist in the United Kingdom, Scandinavia, Canada, New Zealand and Australia (18) . The sensitivity and specificity of both POCTs was slightly lower in the children who were referred by their general paediatrician than those who were referred by their GPs. Therefore, when interpreting our results, the effect of spectrum bias should be taken into account.
As reference standards for diagnosis of IBD, we used endoscopy and 12 months' follow-up, because these are consistent with clinical experience. This may have introduced bias (19) . Nevertheless we feel the risk of misclassifying a child with IBD was extremely low with the introduction of follow-up, given that IBD is a chronic disease that often becomes clinically manifest within 12 months of presentation. Thus, children without high-risk features or a clinical indication for endoscopy over 12 months are very likely not to have IBD. In addition, IBD might have been missed at endoscopy, but persisting symptoms during follow-up may lead to further evaluation, therewith the risk of missing a child with IBD further decreases. Although the decision of the paediatric gastroenterologist was based on structured clinical information, the clinical judgement is to some degree subjective. The triage seemed efficient, because the children who were subjected to an endoscopy at baseline had more frequently high-risk features and higher risk for IBD than children who received no endoscopy at baseline. Although the use of two reference standards is not the ideal situation, following children for 12 months is the best option and represents reality of clinical care (20) .
A GP or paediatrician would only have immediate access to a test result of calprotectine or lactoferrin if all children with abdominal symptoms bring along a sample of faeces. This is not feasible nor desirable. 'Point-of-care' therefore needs some explanation. In daily practice, the diagnostic strategy incorporates two consultations, one in which the test is ordered and a second in which the results are discussed. It is the latter consultation that will increase efficiency because the POCT can be conducted by a GP assistant, results will be available within 15 minutes and the patient can be seen immediately by a GP to discuss the results.
Comparison with existing literature
We found no previous studies that have evaluated the characteristics of POCTs for discriminating IBD from other gastrointestinal disorders in children with chronic gastrointestinal symptoms. In one study, both tests were measured by ELISA and were significantly elevated in children with active IBD (21) . The interaction between both tests was taken to indicate that the tests should be used together. We also expected that calprotectin and lactoferrin had added value to one another, not least because calprotectin showed high sensitivity and lactoferrin showed high specificity (5, 10, 11) . Although lactoferrin had higher specificity than calprotectin, the improvement in diagnostic value of using a combination POCT was not substantial to both tests individually.
In a primary care study of adults with lower gastro-intestinal abdominal symptoms, researchers evaluated the diagnostic performance of both POCTs for identifying IBD (22) . Although they produced comparable specificities to our results, their sensitivities were lower. This might be explained by the adult study population and the use of different test assays and cut-off values.
Implications for research and practice
No physician wants to miss a diagnosis of IBD in children presenting with chronic gastrointestinal symptoms; likewise, he or she must minimize referrals of children without IBD. In primary care, IBD has a low prevalence, so the probability of missing a child with IBD will be small and the probability of a referral of a child with functional gastrointestinal disorder will be high. To reduce the referral rate a test must have high specificity, which both POCTs (especially POCT lactoferrin) showed in the primary care cohort. The low false positive rates have the potential to reduce the number of referrals of children without IBD. The scenario-analysis showed that a normal POCT calprotectin or POCT lactoferrin test in children with high-risk features could reduce the number of referrals with 95% or 100%, respectively. None of the children without high-risk features was diagnosed with IBD during the 12 months follow-up. Therefore, testing with both POCTs seems not of value in children without high-risk features. A disadvantage is that our sample was too small to include sufficient children with IBD in the primary care cohort. Therefore, we could not present positive and negative predictive values.
High sensitivities and negative predictive values are needed to minimize the rate of negative test results in children with IBD, which in turn, can delay further testing and treatment (23) . The high sensitivities and negative predictive values of both POCTs in the referred cohort indicate that it can effectively rule out IBD in children in whom the GP considers referral. In addition, we showed that it could reduce the referral rate by 76% (POCT calprotectin) and 81% (POCT lactoferrin), while missing one child with IBD (6%). What is notable is that this study did not take into account referrals of other organic disease, such as celiac disease. Therefore, the presented numbers of referrals prevented, represent a 'best case scenario' and are applicable as far as IBD is concerned.
A prospective cluster randomized controlled trial is needed to investigate the added value of both POCTs in primary care to effectively refer children for further diagnostic work-up for IBD. Moreover, studies are needed to examine the feasibility and cost-effectiveness of POCT in clinical practice. In our study, the POCTs were not performed at the GP's office, but by experienced laboratory technicians. Therefore, interpretation by an inexperienced GP or medical assistant might be less reliable (e.g. the intensity of the test indicator line can vary). Also, we did not compare the cost and time efficiency of pointof-care testing with sample analyses in a laboratory for ELISA.
Conclusion
A diagnostic test strategy in primary care by using a simple POCT calprotectin or lactoferrin has the potential to reduce the need for referral for further diagnostic work-up in specialist care, with a very low risk of missing a child with IBD. Studies are required to investigate, the feasibility, whether POCTs actually will reduce referrals, and cost-effectiveness of the POCTs in children with chronic gastrointestinal symptoms in primary care.
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